| Hazard Information | Back Directory | [Uses]
Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1]. | [in vivo]
Zelminemab (10 mg/kg; i.v.; once) reduces nociceptive neu-ronal activity in the TCC[2]. | Animal Model: | Sprague-Dawley rats, electricalstimulation was performed on the intact dura mater abovethe middle meningeal artery[2]. | | Dosage: | 10 mg/kg | | Administration: | i.v.; once | | Result: | Induced an inhibition of stimulus-evoked nociceptive activity in the trigeminocervical com-plex (TCC). |
| [References]
[1] Eloisa Rubio-Beltrán, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018 Aug 7;19(1):64. DOI:10.1186/s10194-018-0893-8
[2] Hoffmann J, et al. PAC-1 receptor antibody modulates nociceptive trigeminal activity in rat. Cephalalgia. 2016;36(1S):141–141. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
|